You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
PAIN MANAGEMENT DRUG PANEL, URINE |
||
Geisinger Epic Procedure Code: LAB2802
Geisinger Epic ID: 43799
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Random urine | |
Preferred collection container: |
||
Specimen required: |
15 mL aliquot AND 3 mL aliquot urine; minimum 10 mL and 1 mL, respectively. | |
Special notes: |
Urine temperature should be checked and within range (90-100° F) prior to submission. Orders must include the names of the drugs that require testing. | |
| SPECIMEN PROCESSING |
||
Transport temperature: |
Refrigerated (preferred) or room temperature. | |
Specimen stability: |
Room temperture: 2 days. Refrigerated: 14 days. | |
Rejection criteria: |
Stability limits exceeded. | |
TEST DETAILS |
||
Additional information: |
The lab will perform urine validity testing, urine toxicology screen and other appropriate toxicology testing based on medication information provided. Screening results are presumptive and can only be used for medical purposes. | |
CPT code(s): |
80307 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Amphetamines screen Benzodiazepines screen Cannabinoids screen Cocaine metabolite screen Fentanyl screen Hydrocodone screen Methadone metabolite screen Morphine/Codeine screen Oxycodone screen Specimen Validity Testing Based on the prescription information provided at order, confirmation by LC-MS/MS may be performed at an additional charge. |
|
Methodology: |
KIMS EMIT Homogeneous enzyme immunoassay Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) |
|
Synonyms: |
Compliance testing OBCMT
|
|
Clinical significance: |
PAIN MANAGEMENT DRUG PANEL, URINE and PAIN MANAGEMENT DRUG PANEL, URINE W/ INTERPRETATION are tests used to monitor the compliance of patients who are on opioids and benzodiazepines. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM Sheng-Ying (Margaret) Lo, PhD, DABCC |
|
| Review Date: | 12/29/2022 | |